Earnings Forecast Research on Ironwood Pharmaceuticals, Inc. (IRWD)

Ironwood Pharmaceuticals, Inc. has received $-0.26 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 3 Financial Advisor in the Stock Trading Firms. Among 3 Analysts, Bottom line EPS Estimate for the current quarter is $-0.3 while the top line estimate is $-0.23 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -163.33%.

Ironwood Pharmaceuticals, Inc. reported better than expected with a surprise EPS of 21.74% or $0.05 during its most recent quarterly earnings. The Actual EPS was $-0.18 compared to the Estimated EPS of $-0.23.

In the last quarter, Ironwood Pharmaceuticals, Inc. reported Annual Earnings of $-0.18. Based on the filings, last years Annual Earnings was, $-0.93. In the last Quarter, IRWD reported a surprise Earnings per Share of 21.74% . The consensus estimate for current quarter is $-0.26 and for the current fiscal year, the estimate is $-0.75. For the Next fiscal year, the estimate is $-0.35 based on the consensus.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) : On Tuesday heightened volatility was witnessed in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) which led to swings in the share price. The stock opened for trading at $13.9 and hit $14.48 on the upside , eventually ending the session at $14.38, with a gain of 2.71% or 0.38 points. The heightened volatility saw the trading volume jump to 1,404,367 shares. The 52-week high of the share price is $16.89 and the company has a market cap of $2,103 million. The 52-week low of the share price is at $7.35 .

Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. The Companys first in class compound, Linaclotide, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation and chronic constipation. The Company also focuses on one Phase 1 pain drug candidate and multiple preclinical programs, as well as on building a specialty biochemicals business based on a proprietary strain-development platform. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is headquartered in Cambridge, Massachusetts.


Share this post

Leave a Reply